CN107849135A - 与分拣蛋白结合并抑制颗粒蛋白前体的结合的抗体 - Google Patents

与分拣蛋白结合并抑制颗粒蛋白前体的结合的抗体 Download PDF

Info

Publication number
CN107849135A
CN107849135A CN201680040476.5A CN201680040476A CN107849135A CN 107849135 A CN107849135 A CN 107849135A CN 201680040476 A CN201680040476 A CN 201680040476A CN 107849135 A CN107849135 A CN 107849135A
Authority
CN
China
Prior art keywords
antibody
chain variable
variable domain
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680040476.5A
Other languages
English (en)
Chinese (zh)
Inventor
L·C·比尔曼勒恩
I·J·马里克
J·B·斯塔文哈根
S·克里斯滕森
J·埃格比约
A·格里森
E·范登布林克
P·帕伦
R·德荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Priority to CN202210124751.9A priority Critical patent/CN114478774A/zh
Priority to CN202210124752.3A priority patent/CN114478775A/zh
Publication of CN107849135A publication Critical patent/CN107849135A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680040476.5A 2015-07-13 2016-07-12 与分拣蛋白结合并抑制颗粒蛋白前体的结合的抗体 Pending CN107849135A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202210124751.9A CN114478774A (zh) 2015-07-13 2016-07-12 与分拣蛋白结合并抑制颗粒蛋白前体的结合的抗体
CN202210124752.3A CN114478775A (zh) 2015-07-13 2016-07-12 与分拣蛋白结合并抑制颗粒蛋白前体的结合的抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1512215.3A GB201512215D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods
GB1512215.3 2015-07-13
PCT/EP2016/066516 WO2017009327A1 (en) 2015-07-13 2016-07-12 Antibodies that bind to sortilin and inhibit the binding of progranulin

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202210124751.9A Division CN114478774A (zh) 2015-07-13 2016-07-12 与分拣蛋白结合并抑制颗粒蛋白前体的结合的抗体
CN202210124752.3A Division CN114478775A (zh) 2015-07-13 2016-07-12 与分拣蛋白结合并抑制颗粒蛋白前体的结合的抗体

Publications (1)

Publication Number Publication Date
CN107849135A true CN107849135A (zh) 2018-03-27

Family

ID=54013862

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201680040476.5A Pending CN107849135A (zh) 2015-07-13 2016-07-12 与分拣蛋白结合并抑制颗粒蛋白前体的结合的抗体
CN202210124752.3A Pending CN114478775A (zh) 2015-07-13 2016-07-12 与分拣蛋白结合并抑制颗粒蛋白前体的结合的抗体
CN202210124751.9A Pending CN114478774A (zh) 2015-07-13 2016-07-12 与分拣蛋白结合并抑制颗粒蛋白前体的结合的抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210124752.3A Pending CN114478775A (zh) 2015-07-13 2016-07-12 与分拣蛋白结合并抑制颗粒蛋白前体的结合的抗体
CN202210124751.9A Pending CN114478774A (zh) 2015-07-13 2016-07-12 与分拣蛋白结合并抑制颗粒蛋白前体的结合的抗体

Country Status (35)

Country Link
US (6) US10479835B2 (https=)
EP (1) EP3322726B1 (https=)
JP (2) JP6979397B2 (https=)
KR (1) KR102778576B1 (https=)
CN (3) CN107849135A (https=)
AR (1) AR105335A1 (https=)
AU (1) AU2016292980B2 (https=)
BR (1) BR112018000771A2 (https=)
CA (1) CA2989739A1 (https=)
CL (2) CL2018000092A1 (https=)
CO (1) CO2017012988A2 (https=)
CR (1) CR20180002A (https=)
DO (1) DOP2018000014A (https=)
EA (1) EA201890038A1 (https=)
EC (1) ECSP18002725A (https=)
ES (1) ES3024469T3 (https=)
GB (1) GB201512215D0 (https=)
HR (1) HRP20250602T1 (https=)
HU (1) HUE071424T2 (https=)
IL (1) IL256503B (https=)
JO (1) JO3710B1 (https=)
MA (1) MA42440B1 (https=)
MX (1) MX2018000506A (https=)
NI (1) NI201800007A (https=)
PE (1) PE20181014A1 (https=)
PH (1) PH12018500100A1 (https=)
PL (1) PL3322726T3 (https=)
RS (1) RS66856B1 (https=)
RU (1) RU2735639C2 (https=)
SV (1) SV2018005613A (https=)
TN (1) TN2017000534A1 (https=)
TW (1) TWI760305B (https=)
UA (1) UA125136C2 (https=)
WO (1) WO2017009327A1 (https=)
ZA (1) ZA201708613B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114981297A (zh) * 2019-12-23 2022-08-30 戴纳立制药公司 颗粒蛋白前体变体
WO2024169928A1 (zh) * 2023-02-15 2024-08-22 三优生物医药(上海)有限公司 包含共同轻链的抗体库、其制备方法及其用途

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3280441T1 (sl) 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai
EP3666281A1 (en) * 2018-12-14 2020-06-17 Insusense ApS Compositions comprising sortilin-1
MX2021012335A (es) * 2019-04-10 2021-11-12 Regeneron Pharma Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.
BR112022026508A2 (pt) * 2020-06-24 2023-03-07 Prothena Biosciences Ltd Anticorpos que reconhecem sortilina
KR20250028349A (ko) 2022-06-23 2025-02-28 드라우프니르 바이오 에이피에스 리소좀 내 세포외 표적의 분해를 선택적으로 유도하는 이작용성 분자
WO2025031098A1 (zh) * 2023-08-09 2025-02-13 瑞诺元(苏州)生物科技有限公司 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用
WO2025132764A1 (en) * 2023-12-21 2025-06-26 Amylonix Ab A sortilin-binding polypeptide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022175A1 (en) * 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
CN102439041A (zh) * 2008-12-19 2012-05-02 H.隆德贝克有限公司 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0486622T3 (da) 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
WO1994019935A1 (en) 1993-03-09 1994-09-15 Genzyme Corporation Isolation of components of interest from milk
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
MXPA02000962A (es) 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP1891966B1 (en) 2002-12-20 2012-02-15 H. Lundbeck A/S Modulation of activity of neurotrophins; screening method
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2008076262A2 (en) 2006-12-15 2008-06-26 Merck & Co., Inc. Receptor for amyloid beta and uses thereof
RS60019B1 (sr) 2006-12-21 2020-04-30 H Lundbeck As Modulacija aktivnosti proneurotrofina
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
KR101614558B1 (ko) 2008-04-27 2016-04-22 하. 룬드벡 아크티에셀스카브 인간 소르틸린의 결정 구조 및 소르틸린에 대한 리간드를 확인하기 위한 이의 용도
WO2009154995A2 (en) 2008-05-27 2009-12-23 Kyowa Hakko Kirin Co., Ltd. Interleukin 10 receptor (il-10r) antibodies and methods of use
RU2536232C2 (ru) * 2011-07-01 2014-12-20 Олег Ильич Эпштейн Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
JP6239635B2 (ja) 2012-11-02 2017-11-29 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 血管石灰化の誘導因子であるソルチリン１
SI3280441T1 (sl) 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022175A1 (en) * 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
CN102439041A (zh) * 2008-12-19 2012-05-02 H.隆德贝克有限公司 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BD TRANSDUCTION LABORATORIES: "Purified mouse anti-neurotensin receptor 3 product information-technical data sheet", 《BD TRANSDUCTION LABORATORIES》 *
ESBEN M QUISTGAARD等: "Ligands bind to Sortilin in the tunnel of a ten-bladed beta-propeller domain", 《NAT STRUCT MOL BIOL》 *
LOUIS DE MUYNCK等: "The neurotrophic properties of progranulin depend on the granulin E domain but do not require sortilin binding", 《NEUROBIOLOGY OF AGING》 *
YANQIU ZHENG等: "C-Terminus of Progranulin Interacts with the Beta-Propeller Region of Sortilin to Regulate Progranulin Trafficking", 《PLOS ONE》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114981297A (zh) * 2019-12-23 2022-08-30 戴纳立制药公司 颗粒蛋白前体变体
WO2024169928A1 (zh) * 2023-02-15 2024-08-22 三优生物医药(上海)有限公司 包含共同轻链的抗体库、其制备方法及其用途

Also Published As

Publication number Publication date
CL2018000092A1 (es) 2018-07-06
AU2016292980A1 (en) 2018-01-18
RU2018100824A3 (https=) 2020-01-17
CO2017012988A2 (es) 2018-05-21
EA201890038A1 (ru) 2018-06-29
MX2018000506A (es) 2018-05-11
TN2017000534A1 (en) 2019-04-12
JP2022003058A (ja) 2022-01-11
JP2018529635A (ja) 2018-10-11
US11548950B2 (en) 2023-01-10
MA42440B1 (fr) 2025-05-30
MA42440A (fr) 2018-05-23
US20200190188A1 (en) 2020-06-18
DOP2018000014A (es) 2018-04-15
HUE071424T2 (hu) 2025-08-28
PE20181014A1 (es) 2018-06-26
CN114478774A (zh) 2022-05-13
HRP20250602T1 (hr) 2025-07-18
ZA201708613B (en) 2021-03-31
HK1254356A1 (en) 2019-07-19
TWI760305B (zh) 2022-04-11
JP6979397B2 (ja) 2021-12-15
US20250277040A1 (en) 2025-09-04
CL2020002468A1 (es) 2021-01-29
US20210269524A1 (en) 2021-09-02
CN114478775A (zh) 2022-05-13
EP3322726A1 (en) 2018-05-23
UA125136C2 (uk) 2022-01-19
IL256503B (en) 2022-02-01
PL3322726T3 (pl) 2025-06-23
US10479835B2 (en) 2019-11-19
KR102778576B1 (ko) 2025-03-07
TW201702273A (zh) 2017-01-16
EP3322726C0 (en) 2025-03-12
US10428147B2 (en) 2019-10-01
KR20180030045A (ko) 2018-03-21
US20230159643A1 (en) 2023-05-25
US12331123B2 (en) 2025-06-17
RU2018100824A (ru) 2019-08-13
NI201800007A (es) 2018-10-18
PH12018500100A1 (en) 2018-07-30
AU2016292980B2 (en) 2022-10-06
BR112018000771A2 (pt) 2018-09-25
GB201512215D0 (en) 2015-08-19
ES3024469T3 (en) 2025-06-04
AR105335A1 (es) 2017-09-27
US20180305455A1 (en) 2018-10-25
RU2735639C2 (ru) 2020-11-05
RS66856B1 (sr) 2025-06-30
IL256503A (en) 2018-02-28
US20170267761A1 (en) 2017-09-21
ECSP18002725A (es) 2018-03-31
JO3710B1 (ar) 2021-01-31
WO2017009327A1 (en) 2017-01-19
EP3322726B1 (en) 2025-03-12
CR20180002A (es) 2018-04-09
US10889650B2 (en) 2021-01-12
CA2989739A1 (en) 2017-01-19
SV2018005613A (es) 2018-02-23

Similar Documents

Publication Publication Date Title
US12331123B2 (en) Agent, uses and methods for treatment
US10894833B2 (en) Agents, uses and methods for treatment
HK1254356B (en) Antibodies that bind to sortilin and inhibit the binding of progranulin
EA053189B1 (ru) Средства, пути применения и способы лечения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180327